SL Science Holding Limited (SLBT)
Market Closed
15 Oct, 08:00 PM
NASDAQ (NMS) NASDAQ (NMS) Primary $
1. 55
0
0%
$
846.75M Market Cap
- P/E Ratio
- Div Yield
130,700 Volume
- Eps
$ 1.55
Previous Close Want to track SLBT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
SL Science: A $1.15 Billion Valuation Built On Preclinical Promises
SL Science Holding Limited is rated Sell due to an unsustainable $1.15B valuation built on a strictly preclinical pipeline. SLBT's flagship Gamma Delta T cell therapy targets aggressive solid tumors but has not entered human trials, with a very low probability of success. With only $9M in cash, a $3.82M annual loss, and going-concern doubts, imminent dilution is almost certain without a major partnership.
Seekingalpha | 4 weeks ago
2026 © Marketlog. All Rights Reserved.
